

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

INSIDE INFORMATION POSITIVE PROFIT ALERT FOR THE YEAR ENDED DECEMBER 31, 2023

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and the potential investors that based on the preliminary assessment of the unaudited consolidated management accounts for the year ended December 31, 2023 of the Company (the “**Management Accounts**”), as well as other relevant information currently available to the Board, the Group expects its adjusted net loss (non-IFRS measure)¹ for the year ended December 31, 2023 may be narrowed to between approximately RMB65 million and RMB78 million, representing a decrease of approximately 76.6% to 80.5% year over year. The Board is also pleased to inform the Shareholders that the Group recorded a net profit for the first time in its operating history in the fourth quarter of 2023.

Based on information currently available to the Company, the expected significant year over year decrease in the adjusted net loss (non-IFRS measure) for the year ended December 31, 2023 is primarily attributable to (1) the robust business growth of the Group

¹ We define “adjusted net loss (non-IFRS measure)” as loss for the relevant period and adding back (i) change in fair value of financial liabilities, (ii) share-based compensation expenses, (iii) listing expenses, and (iv) expense related to subsidiaries’ equity financing activities.

in both In-hospital Solution segment and Pharmacy Solution segment, as a result of the commercialization of the Patient-to-Manufacturer model based on the well-established SaaS infrastructure and high penetration in hospitals and pharmacies, (2) the continuously improved operating leverage as a result of the unique business model, the established reputation and network in the industry, and high customer stickiness with high recurring purchases, and (3) the improved efficiency in administrative expenses as a result of the operating leverage and effective cost control.

As at the date of this announcement, the Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2023. The information contained in this announcement is therefore only based on a preliminary review of the Management Accounts and other relevant information currently available to the Board. Such Management Accounts have neither been confirmed nor audited by the Company's independent auditor, nor reviewed by the audit committee of the Company. As such, the actual annual results of the Group for the year ended December 31, 2023 may be different from the disclosure in this announcement. Shareholders and potential investors are therefore advised to read carefully the annual results announcement of the Company for the year ended December 31, 2023, which is expected to be published before the end of March 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, January 29, 2024

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*